Insider · SEC Form 4 filer
Martin Madaus
Past buys: 2 of 4 beat
Companies
Where they file as an insider
Azenta (AZTA) Interim CEO Latest filing Oct 22, 2026
Haemonetics (HAE) Director Latest filing Jul 24, 2026
Repligen (RGEN) Director Latest filing May 14, 2026
Hologic (HOLX) Director Latest filing Apr 7, 2026
Quanterix (QTRX) Director Latest filing Jan 2, 2025
Standard Biotools (LAB) Director Latest filing Oct 20, 2023
Track record
Did their buys beat the typical stock?
Open-market buys5
Quarters checked 6 months later4
Beat the typical stock 2 of 4
Quarters too new to check0
2 of 4 checked quarters beat the typical stock. A past record is data, not a forecast.
Repligen (RGEN) Bought Aug 8, 2025 · $202K · 1,800 shares Behind typical Sep 30, 2025 $133.67 → Mar 31, 2026 $117.82 · −11.9% (typical stock −3.4%)
Hologic (HOLX) Bought May 7, 2025 · $301K · 5,445 shares Beat typical Jun 30, 2025 $65.16 → Dec 31, 2025 $74.49 · +14.3% (typical stock +2.1%)
Azenta (AZTA) Bought Nov 19, 2024 · $201K · 4,940 shares Behind typical Dec 31, 2024 $50.00 → Jun 30, 2025 $30.78 · −38.4% (typical stock −3.4%)
Repligen (RGEN) Bought Jun 14, 2024 · $202K · 1,615 shares Beat typical Jun 30, 2024 $126.06 → Dec 31, 2024 $143.94 · +14.2% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.